View in EDS

Revisiting the use of capecitabine in the era of immunotherapy: Efficacy as second-line and later therapy in recurrent/metastatic head and neck squamous cell carcinoma.

Saved in:
Bibliographic Details
Title: Revisiting the use of capecitabine in the era of immunotherapy: Efficacy as second-line and later therapy in recurrent/metastatic head and neck squamous cell carcinoma.
Authors: Ma J; Department of Pharmacy, University of North Carolina Medical Center, 101 Manning Drive, Chapel Hill, NC 27514, USA. Electronic address: joannacma1@gmail.com., Brooks C; Department of Pharmacy, University of North Carolina Medical Center, 101 Manning Drive, Chapel Hill, NC 27514, USA., Tasoulas J; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Wind LS; Department of Pharmacy, University of North Carolina Medical Center, 101 Manning Drive, Chapel Hill, NC 27514, USA., Sheth S; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA; Department of Medicine, Division of Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA., Gwynn M; Department of Pharmacy, University of North Carolina Medical Center, 101 Manning Drive, Chapel Hill, NC 27514, USA.
Source: Oral oncology [Oral Oncol] 2025 May; Vol. 164, pp. 107293. Date of Electronic Publication: 2025 Apr 10.
Publication Type: Letter
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9709118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0593 (Electronic) Linking ISSN: 13688375 NLM ISO Abbreviation: Oral Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1879-0593
DOI:10.1016/j.oraloncology.2025.107293